EPRX

EUPRAXIA PHARMACEUTICALS INC. EPRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Dec 31

Net income

$-38.58M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$163.63M total
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Loading ratio trend…

About EUPRAXIA PHARMACEUTICALS INC. (EPRX): stock profile, AI score and financials

EUPRAXIA PHARMACEUTICALS INC. (EPRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. EPRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of EPRX by reported 13-F value include Beutel, Goodman & Ltd., Affinity Asset Advisors, BALYASNY ASSET MANAGEMENT L.P., based on the most recent SEC filings. EPRX trades on the Nasdaq exchange and files with the SEC under CIK 1581178. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EUPRAXIA PHARMACEUTICALS INC. directly from SEC EDGAR.

SEC EDGAR: CIK 1581178 →